A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

Exclusion Criteria

• •Has pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
• •Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, current ILD, ILD that cannot be ruled out by imaging at screening, or suspected ILD
• •Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
• •Has history of clinically significant intracranial bleeding or spinal cord bleeding
• •Has active neurologic paraneoplastic syndrome
• •Has history of coronary/peripheral artery bypass graft and/or any coronary/peripheral angioplasty or clinically significant cardiovascular disease such as myocardial infarction, symptomatic congestive heart failure (CHF), and/or uncontrolled cardiac arrhythmia within 6 months before the first dose of study intervention
• •Has other uncontrolled or significant protocol specified cardiovascular disease
• •Has history of arterial thrombosis within 6 months before the first dose of study intervention
• •Has chronic liver disease
• •Has history of allogeneic tissue/solid organ transplant
• •Has history of leptomeningeal disease
• •Is infected with human immunodeficiency virus (HIV) and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
• •Has received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-programmed cell death ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor
• •Has received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids
• •Has known additional malignancy that is progressing or has required active treatment within the past 3 years
• •Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy
• •Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
• •Has major surgery within 4 weeks or minor surgery within 2 weeks of allocation/randomization (or first dose), or is anticipated to require a major surgical procedure during the study